b"Scientific Session Abstracts SATURDAY APRIL 20, 2024 Table 1. Demographics among all-comer TF and AA TAVR patientsAll patients TransfemoralAlternativep-ValueTAVR TAVR(N=3441) (N=3278) (N=l63)Age 81.0 (13) 81.0 (13) 82.0 (12) .117Sex Male 2096 (60.9) 2014 (61.5) 84 (49.7) .003Smoker 299 (8.7) 274 (8.4) 25 (15.2) .004Hypertension 2845 (82.7) 2700 (82.4) 145 (89.0) .033Hyperlipidemia 1841(53.5) 1747 (53.3) 94 (57.3) .296Diabetes 1165(33.9) 1094 (33.4) 71 (43.6) .008CKD 2::111 536 (15.6) 490 (15.0) 46 (28.0) .0001Dialysis 182 (5.3) 167 (5.1) 15(9.1).030Chronic lung diseases 535 (15.6) 488 (14.9) 47(28.9) .001Coronary artery disease 1359 (39.5) 1269 (38.7) 91 (55.2) .0001CABG 465 (13.5) 444 (13.5) 21 (12.8) .907Peripheral artery disease 485 (14.1) 386 (11.8) 99 (60.7) .0001CKD,chronickidneydisease;CABG,coronaryarterybypassgraft;Data are presented as the nunber of patients (column %). P-value is calculated with the Kruskal-Walis test for continuous variables and chi- square or Fisher's exact test for categorical variables as appropriate. Continuous variable presented as median and IQR while categorial variable as numbers and%.42 NDANNUAL MEETING|APRIL 1921, 2024|OCEANSIDE, CA 57"